Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease
Ipsen is in a deal-making mood. On Thursday, the company put down $28 million upfront and another $335 million in biobucks for the rights to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
